Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Dynavax makes vaccine ingredients and a hepatitis B vaccine that it sells to healthcare providers and partners.
Dynavax is a small biotech company that makes the stuff that makes other vaccines work better. Its most famous product is an ingredient called CpG 1018 β a tiny piece of synthetic DNA that acts like a wake-up call, telling the immune system to pay attention and respond harder to whatever vaccine it is paired with. Drugmakers buy this ingredient and mix it into their own shots, and Dynavax collects money through partnerships and supply deals.
The company also sells its own finished product: HEPLISAV-B, a hepatitis B vaccine given to adults. Hepatitis B is a liver virus that can cause long-term damage, and HEPLISAV-B's selling point is convenience β it works in two doses over one month instead of the three doses over six months that older vaccines require. That matters for clinics trying to get people fully protected before they disappear. Dynavax sells it mainly in the United States to healthcare providers and public health programs. The business lives and dies on partnerships, and that is both its strength and its weakness. Deals with bigger drugmakers bring in revenue without Dynavax needing its own global sales force, but those partners control the timing and the scale. If a partner's vaccine program stalls or gets cancelled, the money can shrink fast. The company has also been the subject of persistent acquisition speculation over the years, given its strategic ingredient and its modest size.
One thing worth knowing: Dynavax did not always do this. It started life in the 1990s as Double Helix Corporation, founded by scientists including a Nobel laureate, chasing gene-based drugs β a completely different bet. It later pivoted toward vaccines and immune-boosting technology, which is where the real business ended up. That pivot took years and plenty of burned cash, a reminder that biotech success often looks nothing like the original plan.
Saved answer Β· last researched 15 Nov 2026